Table 1. Baseline characteristics of patients.

	Mizoribine (n=14)		Methotrexate (n=10)
	n	Mean±SD	n	Mean±SD	p
Age (year)		72.9±9.8		70.5±8.7	0,52
Gender					0,70
Female	9		6
Male	5		4
Ethnic origin					1,00
Asian	13		10
European	1		0
Erythrocyte sedimentation rate at diagnosis (mm/hr)†		89.5±25.4		81.4±22.7	0,49
Erythrocyte sedimentation rate >40 mm/hr at diagnosis	12/13		7/7		1,00
C-reactive protein at diagnosis (mg/dL)†		5.8±1.8		10.0±7.2	0,06
Prednisone dose at diagnosis (mg/day)†		20.0±8.8		22.1±7.6	0,59
Duration of prednisone monotherapy (days)		310±466		554±510	0,24
Prednisone dose at baseline (mg/day)		12.1±6.7		11.4±5.6	0,70
Comorbidities, no.
Hypertension	6		5		1,00
Diabetes mellitus	4		3		1,00
Hyperuricemia	1		0		1,00
SD: Standard deviation; † Data were missing for three patients in methotrexate group and one patient in mizoribine group.